• About Adcendo
    • The Story
    • Leadership team
    • Board of Directors
    • Senior Scientific Founders
    • Clinical and Scientific Advisory Board
  • Our science
    • What are ADCs
    • The uPARAP receptor
    • Key publications
  • Investors
    • Corporate presentation
    • Press releases
    • Our investors
  • Careers
    • Open Positions
    • Company values
  • Contact

The Collagen Receptor uPARAP in Malignant Mesothelioma: A Potential Diagnostic Marker and Therapeutic Target (2021)

Oct 23, 2021

The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers (2017)

Apr 26, 2017

Targeting a novel bone degradation pathway in primary bone cancer by inactivation of the collagen receptor uPARAP/Endo180 (2016)

Apr 26, 2016

Extracellular Collagenases and the Endocytic Receptor, Urokinase Plasminogen Activator Receptor-associated Protein/Endo180, Cooperate in Fibroblast-mediated Collagen Degradation (2007)

Apr 26, 2007

uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion (2003)

Apr 26, 2003

Urokinase receptor-associated protein (uPARAP) is expressed in connection with malignant as well as benign lesions of the human breast and occurs in specific populations of stromal cells (2002)

Apr 26, 2002

« Older Entries

Recent Posts

  • Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
  • GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate
  • Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
  • Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting
  • Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Recent Comments

No comments to show.

Adcendo ApS

For all inquiries, please contact adcendo via the e-mail address info@adcendo.com



Privacy Policy
© Adcendo ApS, All rights reserved 2022